

## Contact info

Aidian Oy  
aidian@aidian.eu  
+358 10 309 3000

For orders: orders@aidian.eu

www.aidian.eu

Product	Cat. no.
UniQ PINP RIA, 100 tests Intact aminoterminal propeptide of type I procollagen	132545
UniQ ICTP RIA, 100 tests Carboxyterminal telopeptide of type I collagen	132710
UniQ PIIIINP RIA, 100 tests Intact aminoterminal propeptide of type III procollagen	132709

### References

1. Krege JH et al. PINP as a biological response marker during teriparatide treatment for osteoporosis. *Osteoporos Int.* 2014;25:2159-2171.
2. Burnett-Bowie SM et al. Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates. *J Clin Endocrinol Metab.* 2009;94:1097-1103.
3. Eastell R et al. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. *Curr Med Res Opin.* 2006;22:61-66.
4. Koivula MK et al. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. *Clin Biochem.* 2012;45:920-927.
5. Aktas B et al. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer. *Oncol Rep.* 2013;30:441-447.
6. Leeming et al. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. *Cancer Epidemiol Biomarkers Prev.* 2006;15:32-38.
7. Jakob C et al. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. *Leukemia* 2008;22:1767-1772.
8. Garnero P et al. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. *Arthritis Rheum.* 2010;62:33-43.
9. Pathirana D et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. *J Eur Acad Dermatol Venereol.* 2009;23:1-70.
10. Eschaliere R et al. Extracellular matrix turnover biomarkers predict long-term left ventricular remodeling after myocardial infarction: insights from the REVE-2 study. *Circ Heart Fail.* 2013;6:1199-1205.
11. Parkinson C et al. Pegvisomant-induced serum insulin-like growth factor-1 normalization in patients with acromegaly returns elevated markers of bone turnover to normal. *J Clin Endocrinol Metab.* 2003; 88:5650-5655.
12. Saarela T et al. Effects of short-term dexamethasone treatment on collagen synthesis and degradation markers in preterm infants with developing lung disease. *Acta Paediatr.* 2003;92:588-594.

# For successful disease management.

## UniQ<sup>®</sup> Bone & Tissue Markers



**AIDIAN**

www.aidian.eu

**AIDIAN**

# For successful disease management.

The UniQ Bone and Tissue Markers are well-documented and high quality serum assays with established indication areas. The UniQ Bone & Tissue Marker tests offer a specific means of assessing the **metabolism of type I and type III collagen** in humans. As collagen is the most abundant protein of the body, monitoring of its metabolism can be used to detect and manage diseases of many types.

## Available products

UniQ® PINP RIA

UniQ® ICTP RIA

UniQ® PIIINP RIA



UniQ®

## UniQ® PINP RIA

- An early marker to show treatment efficacy
- For monitoring the treatment of osteoporosis<sup>1,2</sup>
- For encouraging treatment compliance<sup>3</sup>
- For monitoring the treatment in Paget's disease<sup>4</sup>



## UniQ® ICTP RIA

- A specific marker of pathological bone degradation
- For monitoring the treatment of cancer<sup>5</sup>
- Early detection of bone metastases during treatment<sup>6</sup>
- For monitoring the treatment of multiple myeloma<sup>7</sup>
- For monitoring the treatment of rheumatoid arthritis<sup>8</sup>



## UniQ® PIIINP RIA

- For detecting changes in the metabolism of connective tissue
- For monitoring liver fibrosis, especially on methotrexate treated psoriasis patients – decreasing the need for liver biopsies<sup>9</sup>
- For monitoring the healing process after myocardial infarction<sup>10</sup>
- For monitoring growth hormone treatment<sup>11</sup>
- For monitoring glucocorticoid treatment<sup>12</sup>



Type I collagen is present mostly in bones. The concentration of **PINP** in the blood is directly related to the amount of new type I collagen laid down in bone, and can be measured from serum samples with UniQ PINP assay.

**ICTP** is found in blood as a result of pathological degradation of mature type I collagen. UniQ ICTP assay measures ICTP concentrations from serum samples.

Synthesis of type III collagen can be demonstrated by measuring the concentration of **PIIINP** from serum samples with UniQ PIIINP assay.